Bacillus coagulans MZY531 在小鼠H22肝细胞癌细胞上通过抗增殖和诱导凋亡的方式具有抗癌潜力。
Anticancer potential of Bacillus coagulans MZY531 on mouse H22 hepatocellular carcinoma cells via anti-proliferation and apoptosis induction.
发表日期：2023 Sep 13
作者：
Zhongwei Zhao, Qian Yang, Tingting Zhou, Chunhong Liu, Manqing Sun, Xinmu Cui, Xuewu Zhang
来源：
Cellular & Molecular Immunology
摘要：
最近，我们发现梭状芽孢杆菌表现出对抗癌的效果，但关于其对肝癌增值的影响和凋亡相关信号通路影响机制的详细阐述仍然缺乏研究。本研究旨在评估梭状芽孢杆菌 MZY531 的抗增值效应以及对小鼠 H22 肝细胞癌细胞系的诱导凋亡作用。通过细胞计数酶-8（CCK-8）分析评估梭状芽孢杆菌 MZY531 的抗增值活性，采用末端脱氧核苷酸转移酶（TDT）介导的dUTP尾标法（TUNEL）染色和流式细胞术分析细胞凋亡情况。通过免疫印迹分析确定与凋亡相关蛋白的表达情况。CCK-8分析发现梭状芽孢杆菌 MZY531以浓度依赖性方式抑制H22细胞的增殖。TUNEL染色发现，在梭状芽孢杆菌 MZY531 干预后，H22细胞的凋亡率增加。此外，流式细胞术分析显示，与对照组相比，梭状芽孢杆菌 MZY531处理（MOI= 50和100）明显减轻了H22细胞的凋亡。免疫印迹分析发现梭状芽孢杆菌 MZY531显著降低了磷酸化-PI3K（p-PI3K），磷酸化-AKT（p-AKT）和磷酸化-mTOR（p-mTOR）的水平。此外，H22细胞处理梭状芽孢杆菌 MZY531使caspase-3和Bax的表达增加，Bcl-2的表达受到损害。综上所述，通过PI3K/AKT/mTOR和Bax/Bcl-2/Caspase-3通路的凋亡诱导和细胞增殖抑制为梭状芽孢杆菌 MZY531作为潜在的抗癌治疗药物提供了有希望的证据。©2023. BioMed Central Ltd., part of Springer Nature.
Bacillus coagulans have recently revealed its anticancer effects, but few investigations are available on their effects on liver cancer proliferation, and the precise mechanism to mark its impact on apoptosis-related signaling pathways has yet to be elucidated. The aim of this study was to evaluate the anti-proliferative effect of B. coagulans MZY531 and apoptosis induction in the mouse H22 hepatocellular carcinoma cell line. The anti-proliferative activity of B. coagulans MZY531 was evaluated by Cell Counting Kit-8 (CCK-8) assay, and cell apoptosis was revealed with Terminal Deoxynucleotidyl Transferase (TDT)-mediated dUTP Nick-End Labeling (TUNEL) staining and flow cytometric analysis. The expressions of apoptosis-related protein were determined by western blot analysis. The CCK-8 assay revealed that B. coagulans MZY531 inhibited the H22 cells proliferation in a concentration-dependent manner. TUNEL staining revealed an increased apoptosis rate in H22 cells following intervention with B. coagulans MZY531. Furthermore, flow cytometric analysis showed that B. coagulans MZY531 treatment (MOI = 50 and 100) significantly alleviated the H22 cells apoptosis compared with the control group. Western blot analysis found B. coagulans MZY531 significantly decreased level of phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), and phospho-mTOR (p-mTOR) compared with the control group. Furthermore, H22 cells treatment with B. coagulans MZY531 enhanced the expression of caspase-3 and Bax and jeopardized the expression of Bcl-2. Taken together, apoptosis induction and cell proliferation inhibition via PI3K/AKT/mTOR and Bax/Bcl-2/Caspase-3 pathway are promising evidence to support B. coagulans MZY531 as a potential therapeutic agent for cancer.© 2023. BioMed Central Ltd., part of Springer Nature.